Phaseline

Companies › Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 4; Infectious disease, Oncology; next expected readout Feb 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Eravacycline
Bacterial 70S ribosome inhibitor
–Phase 2Complicated Intra-abdominal Infections (cIAI); Infections, Bacterial; Hematological MalignancyFeb 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06440304EravacyclinePhase 4Infections, BacterialInfectious diseaseDec 2026
NCT05537896EravacyclinePhase 2Hematological MalignancyOncologyFeb 2028
NCT06794541EravacyclinePhase 2Complicated Intra-abdominal Infections (cIAI)Infectious diseaseFeb 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Amivas Cantex Pharmaceuticals The Skin Center Dermatology Group NanoEcho Syncromune

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.